Liraglutide and exenatide are both earlier-generation GLP-1 receptor agonists — predecessors to today's semaglutide and tirzepatide. They share a mechanism (mimicking the gut hormone GLP-1) but differ in their molecular origin and dosing. Both are FDA-approved and produce modest weight loss compared with the newer agents.
At a glance
| Liraglutide | Exenatide | |
|---|---|---|
| Class | GLP-1 receptor agonist (human-GLP-1 based) | GLP-1 receptor agonist (exendin-4 based) |
| Brand names | Victoza, Saxenda | Byetta, Bydureon |
| FDA status | Approved | Approved |
| Dosing | Once daily | Twice daily (Byetta) or weekly (Bydureon) |
| Weight loss | Modest | Modest |
| Origin | Modeled on human GLP-1 | Derived from exendin-4 (Gila monster) |
The bottom line
Bottom line: Two foundational GLP-1 drugs, both now largely overtaken by more potent successors. Liraglutide is based on human GLP-1 and dosed daily (with a dedicated weight product, Saxenda); exenatide is based on exendin-4 and comes in twice-daily or weekly forms. Both are approved and effective, just less powerful than newer agents.
Frequently asked questions
What's the difference between liraglutide and exenatide?
Both are early GLP-1 receptor agonists, but liraglutide is modeled on human GLP-1 and dosed once daily, while exenatide is derived from exendin-4 (originally from Gila monster venom) and comes in twice-daily or weekly forms.
Are liraglutide and exenatide still used?
Yes, but both have been largely overtaken by newer, more potent GLP-1 agents like semaglutide and dual agonists like tirzepatide, which offer greater weight loss and more convenient dosing.
Which causes more weight loss?
Both produce modest weight loss, less than newer agents. Liraglutide has a dedicated higher-dose weight-management product (Saxenda). Both are prescription medicines used under medical supervision.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med. 2015. Peer-reviewed study
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016. Peer-reviewed study
- Guo T, Yan W, Cui X, et al. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Mol Med. 2023. Peer-reviewed study
- Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014. Peer-reviewed study
- Ni XY, Feng XJ, Wang ZH, et al. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. Acta Pharmacol Sin. 2024. Peer-reviewed study
- Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020. Peer-reviewed study
- Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone GLP-1. Expert Opin Drug Discov. 2013. Peer-reviewed study
- Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2006. Peer-reviewed study
- Bray GM. Exenatide. Am J Health Syst Pharm. 2006. Peer-reviewed study
- Barnett AH. Exenatide. Drugs Today (Barc). 2005. Peer-reviewed study
- Barnett A. Exenatide. Expert Opin Pharmacother. 2007. Peer-reviewed study
- Mullins RJ, Mustapic M, Chia CW, et al. A Pilot Study of Exenatide Actions in Alzheimer's Disease. Curr Alzheimer Res. 2019. Peer-reviewed study